Conversely, some studies suggest that long-term use of exogenous insulin or insulin secretagogues may slightly increase pancreatic cancer risk, possibly because hyperinsulinemia persistently activates the insulin/IGF-1 receptor pathway and promotes cell proliferation (28, 29). The gene discussed is INS; the disease is pancreatic neoplasm.